Abstract:Background: Nonalcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide. It is subdivided into nonalcoholic fatty liver (NAFL) and the more aggressive form, nonalcoholic steatohepatitis (NASH), which carries a higher risk of developing fibrosis and cirrhosis. There is currently no reliable non-invasive method for differentiating NASH from NAFL. Purpose: To investigate the ability of magnetic resonance imaging (MRI)-based imaging biomarkers to diagnose NASH and moderate fibrosis as well as assess their repeatability. Study type: Prospective. Subjects: Sixty-eight participants (41% women) with biopsy-proven NAFLD (53 NASH and 15 NAFL). Thirty participants underwent a second MRI in order to assess repeatability. Field strength/sequence: 3.0 T; MR elastography (MRE) (a spin-echo echo-planar imaging [SE-EPI] sequence with motion-encoding gradients), MR proton density fat fraction (PDFF) and R2* mapping (a multi-echo three-dimensional gradient-echo sequence), T1 mapping (a single-point saturation-recovery technique), and diffusion-weighted imaging (SE-EPI sequence). Assessment: Quantitative MRI measurements were obtained and assessed alone and in combination with biochemical markers (cytokeratin-18 [CK18] M30, alanine transaminase [ALT], and aspartate transaminase [AST]) using logistic regression models. Models that could differentiate between NASH and NAFL and between moderate to advanced fibrosis (F2-4) and no or mild fibrosis (F0-1), based on the histopathological results, were identified. Statistical tests: Independent samples t-test, Pearson's chi-squared test, area under the receiver operating characteristic curve (AUROC), Spearman's correlation, intra-individual coefficient of variation, and intraclass correlation coefficient (ICC). Statistical significance was set at P < 0.05. Results: There was a significant difference between the NASH and NAFL groups with liver stiffness assessed with MRE, CK18 M30, and ALT, with an AUROC of 0.74, 0.76, and 0.70, respectively. Both MRE and PDFF contributed significantly to a bivariate model for diagnosing NASH (AUROC = 0.84). MRE could significantly differentiate between F2-4 and F0-1 (AUROC = 0.74). A model combining MRE with AST improved the diagnosis of F2-4 (AUROC = 0.83). The ICC for repeatability was 0.94 and 0.99 for MRE and PDFF, respectively. Data conclusion: MRE can potentially diagnose NASH and differentiate between fibrosis stages. Combining MRE with PDFF improves the diagnosis of NASH. Level of evidence: 2 TECHNICAL EFFICACY: Stage 2.

Combined and Sequential Non-Invasive Approach to Diagnosing Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease and Persistently Normal Alanine Aminotransferase Levels.

NAFL Screening Score: A Basic Score Identifying Ultrasound-Diagnosed Non-Alcoholic Fatty Liver

Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis

Ratio Of Conjugated Chenodeoxycholic To Muricholic Acids Is Associated With Severity Of Nonalcoholic Steatohepatitis

Technical Acoustic Measurements Combined with Clinical Parameters for the Differential Diagnosis of Nonalcoholic Steatohepatitis

Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis

A Novel Non-Invasive Approach Based on Serum Ceruloplasmin for Identifying Non-Alcoholic Steatohepatitis Patients in the Non-Diabetic Population

Diagnostic Value of CK-18, FGF-21, and Related Biomarker Panel in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease

Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study

Serum Golgi Protein 73 As a Potential Biomarker for Hepatic Necroinflammation in Population with Nonalcoholic Steatohepatitis

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

IDDF2022-ABS-0120 Hepatocyte Apoptosis Fragment Product Cytokeratin-18 M30 and Non-Alcoholic Steatohepatitis Risk Prediction: an International Registry Study

[Value of a Two-Step Approach with Cytokeratin-18 and Controlled Attenuation Parameter in Noninvasive Differential Diagnosis of Nonalcoholic Steatohepatitis].

Development, Validation, and Application of a Scoring Model for Non-alcoholic Steatohepatitis

The Combination of MR Elastography and Proton Density Fat Fraction Improves Diagnosis of Nonalcoholic Steatohepatitis

Fully connected neural network-based serum surface-enhanced Raman spectroscopy accurately identifies non-alcoholic steatohepatitis

Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design

A novel quantitative ultrasound technique for identifying non‐alcoholic steatohepatitis

Serum Biomarkers Combined with Ultrasonography for Early Diagnosis of Non-Alcoholic Fatty Liver Disease Confirmed by Magnetic Resonance Spectroscopy

Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4